Cara Therapeutics, Inc. (Nasdaq: CARA) announced that it has initiated patient recruitment for an adaptive Phase 2/3 trial of I.V ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE